News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Viamet Pharmaceuticals Initiates Phase 1 Clinical Program with Novel Antifungal Agent VT-1161


9/14/2011 10:34:41 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology. VT-1161 has been shown in preclinical studies to potently inhibit a wide range of fungal pathogens causing human disease, while maintaining a very significant safety margin. The initial Phase 1 study, a single-ascending dose trial in healthy volunteers, is currently being conducted in the United States.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES